An anchoring protein, ZFYVE9 (SARA), recruits SMAD2/3 MH2 domain mutants

Stable Identifier
R-HSA-3702153
Type
Reaction
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Summation

As SMAD2 and SMAD3 MH2 domain mutations mainly affect amino acid residues involved in SMAD oligomerization (Fleming et al. 2013) and not residues involved in SMAD2/SMAD3 binding to ZFYVE9 (SARA) (Wu et al. 2000), it is assumed that SARA can recruit SMAD2/3 MH2 domain mutants to activated TGF-beta receptor 1 (TGFBR1), but this has not been experimentally examined.

Literature References
PubMed ID Title Journal Year
23139211 SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer

Fleming, NI, Jorissen, RN, Mouradov, D, Christie, M, Sakthianandeswaren, A, Palmieri, M, Day, F, Li, S, Tsui, C, Lipton, L, Desai, J, Jones, IT, McLaughlin, S, Ward, RL, Hawkins, NJ, Ruszkiewicz, AR, Moore, J, Zhu, HJ, Mariadason, JM, Burgess, AW, Busam, D, Zhao, Q, Strausberg, RL, Gibbs, P, Sieber, OM

Cancer Res. 2013
10615055 Structural basis of Smad2 recognition by the Smad anchor for receptor activation

Wu, G, Chen, YG, Ozdamar, B, Gyuricza, CA, Chong, PA, Wrana, JL, Massagué, J, Shi, Y

Science 2000
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
protein binding activity of ZFYVE9-1 [early endosome membrane]
Physical Entity
Activity
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed